biotech
biotech Articles
Axovant Sciences shares cratered early on Tuesday after the firm provided an update from its late-stage Alzheimer’s trial.
Published:
Last Updated:
Biopharmaceutical company Zai Lab intends to price its 8 million shares in the range that results in an initial public offering valued up to more than $165 million.
Published:
Last Updated:
Biotech companies may attempt a secondary offering after seeing a run in the share price. So now seems the as good a time as any for MediWound to capitalize in 2017.
Published:
Last Updated:
Dimension Therapeutics saw one of the largest gains on the day after it came to light that the firm received an acquisition offering from Ultragenyx Pharmaceutical.
Published:
Last Updated:
Shares of Pluristem Therapeutics saw a handy gain early Monday after the company said it had received a key update from the FDA.
Published:
Last Updated:
Nabriva Therapeutics watched its shares more than double to kick off the week after the firm announced results from its late-stage trial in patients with community-acquired bacterial pneumonia.
Published:
Last Updated:
Nightstar Therapeutics intends to price more than 5 million shares in a range that results in an initial public offering valued up to more than $92 million.
Published:
Last Updated:
Gene therapy company Krystal Biotech expects to price 3 million shares so that the entire offering is valued up to nearly $38 million.
Published:
Last Updated:
Array BioPharma saw its shares turn negative early on Thursday after the firm announced a secondary offering.
Published:
Last Updated:
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an...
Published:
Last Updated:
The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
Sage Therapeutics saw its shares drop by about a quarter early on Tuesday after the firm gave an update on its late-stage study trial in the treatment super-refractory status epilepticus.
Published:
Last Updated:
Kura Oncology saw its shares double early Friday after the firm announced results from its mid-stage trial in patients with squamous cell carcinomas.
Published:
Last Updated:
Usually when a clinical study is stopped it spells disaster for the company performing the study, but in this case Bristol-Myers Squibb is bucking that trend and investors are thrilled.
Published:
Last Updated:
Celgene received an update from the FDA early on Thursday. Although shares did not dip initially, this action could prove to be problematic for the biotech giant going forward.
Published:
Last Updated: